In a mouse model of cervical cancer, the STING agonist MSA-2, in combination with a PD-1 monoclonal antibody, significantly prolonged the survival cycle of mice, and MSA-2 administration remodeled the TME and exerted anti-tumor activity in mice (105). Here, STING1 is linked to neoplasm.